content_image/292024.jpg content_image/292026.jpg content_image/292029.jpg
In Europe, the Middle East and Africa, Astellas has an expansive business platform, selling products in around 70 countries through more than 20 sales subsidiaries and external distributors. 

Our strategic priorities are to expand the urology franchise, sustain the transplantation business, and quickly establish a business platform in the oncology field. In fiscal 2013, we continued to achieve growth in the OAB fran- chise combining Vesicare and BETMIGA as we worked to develop a sales organization in preparation for the launch of XTANDI. 

The business environment is being reshaped by various trends including the increasing importance of economic assessments in determining drug reim- bursement prices, as well as more stringent polices to curb medical expendi- tures in line with fiscal austerity measures. Meanwhile, emerging markets continue to expand. 

We will respond flexibly to these changes in the environment and ensure that we seize on opportunities to expand business with the aim of driving sustained growth. 

## Sales of Major Products 

<img src='content_image/292024.jpg'>

<img src='content_image/292026.jpg'>

<img src='content_image/292029.jpg'>

